Announcement • Jul 16
BioAdaptives Outlines Xcellara Platform Strategy And Announces Commercial Launch Of XcellaraHeart BioAdaptives Inc. outlined the scientific strategy behind its Xcellara cellular wellness platform ahead of the August 1, 2026, commercial launch of XcellaraHeart. The platform addresses a fundamental biological challenge: while increasing circulating stem cells yields substantial health benefits, maximizing their impact requires directing those cells to specific locations in the body. To address this, the Xcellara platform combines two complementary pillars: Supply and Direction. The supply pillar is anchored in the Xcellara base, validated by a human randomized controlled trial that documented an average 268.8% increase in circulating stem/progenitor-type cells. The direction pillar is achieved by pairing this base with tissue-specific ingredients that support the body's natural signaling pathways (such as the SDF-1a/CXCR4 chemokine axis), guiding the mobilized cells to specific target areas. XcellaraHeart is the first commercial application of this platform strategy. The formula combines the Xcellara mobilization base with Tanshinone IIA, a Danshen-derived compound studied in cardiovascular research for its effects on the SDF-1a/CXCR4 signaling pathways involved in cellular trafficking and cardiovascular repair-response biology. SDF-1a is a chemokine — a chemical signal — that circulating stem and progenitor cells respond to via their CXCR4 receptors, directing them toward tissues that are signaling for support. Published research has examined Tanshinone IIA's role in upregulating this pathway in cardiac tissue. The Xcellara base is supported by human clinical data showing a substantial increase in circulating primitive stem/progenitor-type cells. BioAdaptives is developing a series of targeted Xcellara derivative formulas across multiple wellness categories, including mobility and joint support, skin and collagen matrix support, nerve comfort and cognitive wellness, metabolic resilience, and other areas where cellular supply and tissue-signaling support may provide a rational framework for product development. The Company intends to introduce new formulas on a regular cadence, with each product targeting a distinct wellness area and featuring an ingredient rationale built on the same mobilization base. The Company’s flagship Xcellara base formula is the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks, with zero adverse effects on more than twenty blood parameters. The Xcellara product line includes seven targeted formulas that combine the clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications. The complete scientific evidence dossier for the XcellaraHeart formulation will be available. The dossier separates findings from BioAdaptives’ human clinical research on the Xcellara base, published research on Tanshinone IIA, and the Company’s product-development rationale for combining the two. XcellaraHeart will be available for order starting August 1, 2026, with first deliveries expected shortly thereafter. General information on new products awaiting rollout is available. Announcement • Jul 15
Bioadaptives Inc Announces Commercial Availability of Xcellaraheart Cardiovascular Wellness Formula BioAdaptives Inc. announced the upcoming commercial availability of XcellaraHeart, a premium cardiovascular wellness formula that integrates two complementary areas of cellular health science: stem/progenitor cell mobilization and cardiovascular repair signaling support. XcellaraHeart is built on the Company’s Xcellara base, which is supported by a randomized, double-blind, placebo-controlled human clinical trial documenting an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks. The Company believes this clinical result provides a strong foundation for XcellaraHeart’s supply-side strategy: maintaining a healthy circulating pool of stem/progenitor-type cells. The second component of the formula is Tanshinone IIA, a natural bioactive compound derived from Danshen root (Salvia miltiorrhiza). Tanshinone IIA has been studied in peer-reviewed cardiovascular research for its effects on the SDF-1a/CXCR4 chemokine axis, a signaling pathway linked to cellular trafficking, cardiovascular repair biology, and tissue-specific signaling. XcellaraHeart was developed around a two-part cardiovascular-wellness strategy: 1) Supply: The Xcellara base is supported by a randomized, double-blind, placebo-controlled human clinical trial showing an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks. 2) Signaling: Tanshinone IIA has been studied for its effects on the SDF-1a/CXCR4 signaling pathway, which is associated with cellular trafficking and cardiovascular repair-response biology. BioAdaptives developed XcellaraHeart based on the hypothesis that increasing circulating stem/progenitor-type cells may be more meaningful when paired with nutrients that support tissue-specific signaling pathways. The Company believes Tanshinone IIA is a particularly compelling candidate for cardiovascular wellness because of its long research history and published evidence on cardiovascular signaling pathways. The complete scientific evidence dossier for the formulation is available. The dossier will separate findings from BioAdaptives’ human clinical research on the Xcellara base, published research on Tanshinone IIA, and the Company’s product-development rationale for combining the two. XcellaraHeart will be available for order starting Aug. 1, 2026, with first deliveries expected in early August. General information on new products awaiting rollout is available. BioAdaptives Inc. is the developer of the Xcellara line of stem cell mobilization and tissue-homing supplements. The Company’s flagship Xcellara base formula is the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks with zero adverse effects on more than twenty blood parameters. The Xcellara product line includes seven targeted formulas combining the clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications. The complete scientific evidence dossier for the XcellaraHeart formulation will be available. The dossier separates what has been demonstrated in BioAdaptives’ human clinical research on the Xcellara base from published research on Tanshinone IIA and from the Company’s product-development rationale for combining the two. XcellaraHeart will be available for order starting August 1, 2026, with first deliveries expected soon after. General information on new products awaiting rollout is available. These statements have not been evaluated by the Food and Drug Administration. XcellaraHeart is not intended to diagnose, treat, cure, or prevent any disease. Xcellara is a trademark of BioAdaptives Inc. Announcement • Jun 26
BioAdaptives Completes MyndRenew Platform with TruShield Certification of MyndRenew Securing Full Wada Compliance BioAdaptives announced that its nighttime repair formula, MyndRenew, has received TruShield Certified status. This independent verification confirms that MyndRenew meets the rigorous anti-doping standards of the World Anti-Doping Agency (WADA) and the Ultimate Fighting Championship (UFC). Combined with the prior TruShield certification of MyndMed (the daytime performance formula), the full MyndSystem duo is now officially cleared for use by professional fighters and athletes subject to strict anti-doping protocols. With this certification, MyndRenew joins MyndMed — which received TruShield clearance in August 2025 — to form the first complete, fully WADA-compliant 24/7 cognitive performance and repair system for professional athletes. MyndSystem was originally developed for UFC fighters. The platform has since shown strong results across three key demographics that face similar challenges of accelerated brain stress and cognitive wear: professional fighters in their 20s, high-performing executives in their late 30s and 40s, and active seniors aged 55 and older. This broad applicability underscores the platform’s science-backed approach to daytime cognitive performance (MyndMed) and overnight brain repair and recovery (MyndRenew). The certification enhances BioAdaptives’ credibility and competitive differentiation within the premium performance nutrition category. The key potential benefits of the MyndSystem include: Access to Elite Athlete Markets — Official clearance opens pathways to inclusion in UFC-approved supplement pools and similar programs used by other professional leagues, such as the NFL, NBA, and NHL. Broader Consumer Trust — Independent WADA-level verification builds confidence among athletes, coaches, teams, and performance-focused consumers across all three target demographics. Market Expansion Opportunity — The platform’s proven relevance to fighters, executives, and seniors enables multiple high-value revenue streams across the sports nutrition, corporate wellness, and longevity markets. Long-Term Brand and Shareholder Value — This milestone supports brand elevation, potential strategic partnerships, and sustainable growth as the company scales the commercialization of the MyndSystem platform. MyndSystem, MyndMed, and MyndRenew are now available. A 30-day supply of the complete MyndSystem is available as a one-time purchase for $159.90 or via subscription (cancel anytime) for $119.93. A 14-Day Discovery Pack of both is available for $59.95. All products include a 100-day money-back guarantee. Additional product information, full ingredient profiles, and supporting research are also available. 
